Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Active, not recruiting · NCT05583149 · Registry updated 2026-01-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | B-cell neoplasm, Digestive System Diseases, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, aggressive B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, digestive system disorder, hypertrophic pyloric stenosis, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, pyloric stenosis, stomach disorder | Active, not recruiting | Phase 2 | 2026-01-29 | NCT05583149 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Patrick C. Johnson, MD | 3 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth-Israel Deaconess Medical Center | Boston | United States | 5 |
| Massachusetts General Hospital | Boston | United States | 39 |